European Association for Haematopathology
The European Association for Haematopathology (EAHP) is a professional society whose aim is to study diseases of the haematopoietic and lymphoid systems and to promote the exchange and dissemination of knowledge concerning the diagnosis and treatment of these diseases.
we promiss you :
- Membership benefits
- Professional networking
- Contact with fellow haematopathologists and professionals from all over the world
- Up-to-date information about interesting workshops, meetings and conferences
- Participation in the biannual conference (September 2022 in Florence, Italy)
- Lots of information about education for young professionals
Society for Hematopathology .
The Society for Hematopathology (SH) is a professional society for scientists in the clinical, morphological and functional aspects of the hematopoietic and lymphoreticular systems. It was founded in 1981 by Drs. Costan W. Berard and Ronald F. Dorfman. The purpose of the Society was to stimulate interest, investigation, exchange and dissemination of knowledge concerning the clinical, morphological and functional aspects of the hematopoietic and lymphoreticular systems.
The bone marrow symposium will be focused on “Novel frontiers in molecular diagnosis of myeloid neoplasms: biomarkers and integrative prognostic models in myeloid diseases” the aim is to understand how a proper integration of morphological, clinical and molecular data is essential in reaching a correct diagnosis and to guide treatment decision. Topics to be discussed will include the prognostic and clinical significance of new genetic markers or combinations of genetic markers, the paradigm of targeting oncogenic tyrosine kinase signaling in myeloid neoplasia, and the importance of doing genetic analysis in unusual presentation of myeloid diseases or as marker of disease progression.
- Abstract submission subject headings
- Clonality analysis and the role of NGS
- NGS panels for diagnosis, including molecular algorithms
- Structural chromosomal alterations in lymphoma
- The clinical impact of innovative technologies in the management of lymphoma patients
- Other topics including recent advances
The lymphoma symposium will be devoted to “Novel frontiers in molecular diagnosis of lymphoma: biomarkers and integrative prognostic models”. It will explore how best to integrate into our daily clinical practice the plethora of new technologies that help us understand lymphoma biology and are key to pathological classification. The clinical impact of innovative technologies in the management of lymphoma patients will be discussed.
- New horizons in clonality detection
- NGS Panel-sequencing for mutations in a diagnostic setting
- Lymphomas defined by structural chromosomal alterations
- The clinical impact of innovative technologies in the management of lymphoma patients
- Recent advances
Clonality Analysis and the Role of NGS
Clonality analysis is a critical technique in medical and research fields, particularly in oncology, immunology, and hematological studies. It helps determine whether a population of cells originates from a single ancestor (monoclonal) or multiple origins (polyclonal), providing valuable insights into disease progression, tumor evolution, and immune response. Next-Generation Sequencing (NGS) has revolutionized clonality analysis by offering high-resolution, high-throughput, and unbiased sequencing capabilities. Unlike traditional methods such as PCR or Sanger sequencing, NGS enables comprehensive profiling of genetic rearrangements, somatic mutations, and clonal diversity at an unprecedented scale. This technology is especially beneficial for detecting minimal residual disease (MRD), monitoring therapy response, and identifying novel therapeutic targets in cancer and autoimmune disorders. By providing deep sequencing coverage and precise quantification of clonal populations, NGS enhances the accuracy and reliability of clonality assessments, paving the way for personalized medicine and improved patient outcomes.
